← Back to patent-cliff list
R-fluoxetine
Tier C — Watch / tradeR-fluoxetine
Sunovion Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：SERT
Indications (approved)：分离性焦虑, Anxiety, Anxiety disorder
Regional status
US
Phase III
2021-02-09
EU
-
China
-
Japan
-
Synthetic routes & intermediates9 routes
Originator routes × 1Optimised (non-patent) × 8Process routes × 0
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
OriginatorRoute 1Steps 10 · Total yield 0.49 g (R-fluoxetine)
R-fluoxetine-00172-18-4R-fluoxetine-00213734-41-3R-fluoxetine-0033886-69-9R-fluoxetine-004514214-80-3R-fluoxetine-00580650-85-7R-fluoxetine-0061375257-30-9R-fluoxetine-0071375257-29-6R-fluoxetine-0081375257-24-1R-fluoxetine-0091375257-37-6R-fluoxetine-010210546-29-5R-fluoxetine-011115290-81-8R-fluoxetine-012402-44-8R-fluoxetine100568-03-4API · R-fluoxetine
| Code | CAS No. | Intermediate |
|---|---|---|
| R-fluoxetine-001 | 72-18-4 | (S)-2-amino-3-methylbutanoic acid |
| R-fluoxetine-002 | 13734-41-3 | (tert-butoxycarbonyl)-L-valine |
| R-fluoxetine-003 | 3886-69-9Available | (R)-1-phenylethan-1-amine |
| R-fluoxetine-004 | 514214-80-3 | tert-butyl ((S)-3-methyl-1-oxo-1-(((R)-1-phenylethyl)amino)butan-2-yl)carbamate |
| R-fluoxetine-005 | 80650-85-7 | (S)-2-amino-3-methyl-N-((R)-1-phenylethyl)butanamide |
| R-fluoxetine-006 | 1375257-30-9 | (S)-3-methyl-N1-((R)-1-phenylethyl)butane-1,2-diamine |
| R-fluoxetine-007 | 1375257-29-6 | (S)-4-isopropyl-1-((R)-1-phenylethyl)imidazolidin-2-one |
| R-fluoxetine-008 | 1375257-24-1 | (S)-3-acetyl-4-isopropyl-1-((R)-1-phenylethyl)imidazolidin-2-one |
| R-fluoxetine-009 | 1375257-37-6 | (S)-3-((R)-3-hydroxy-3-phenylpropanoyl)-4-isopropyl-1-((R)-1-phenylethyl)imidazolidin-2-one |
| R-fluoxetine-010 | 210546-29-5 | (R)-3-hydroxy-N-methyl-3-phenylpropanamide |
| R-fluoxetine-011 | 115290-81-8 | (R)-3-(methylamino)-1-phenylpropan-1-ol |
| R-fluoxetine-012 | 402-44-8 | 1-fluoro-4-(trifluoromethyl)benzene |
| R-fluoxetine | 100568-03-4 | - |
OptimisedRoute 2Steps 4 · Total yield /
(A)131699-1-a402-45-9(I)131699-1-a3506-36-3(II)131699-1-a—(III)131699-1-a79130-51-1(IV)131699-1-a56225-81-1(V)131699-1-a57226-06-9API · R-fluoxetine
| Code | CAS No. | Intermediate |
|---|---|---|
| (A)131699-1-a | 402-45-9 | 4-(Trifluoromethyl)phenol |
| (I)131699-1-a | 3506-36-3 | 3-(Dimethylamino)-1-phenylpropan-1-one |
| (II)131699-1-a | - | 3-(Dimethylamino)-1-phenyl-1-propanol |
| (III)131699-1-a | 79130-51-1 | (3-Chloro-3-phenylpropyl)dimethylamine |
| (IV)131699-1-a | 56225-81-1 | N,N-Dimethyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine |
| (V)131699-1-a | 57226-06-9 | cyano(methyl){3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl}amine |
OptimisedRoute 3Steps 7 · Total yield /
(I)263642-1-a98-86-2(II)263642-1-a103-67-3(III)263642-1-a5409-62-1(IV)263642-1-a754155-04-9(V)263642-1-a115290-81-8(VI)263642-1-a98-56-6API · R-fluoxetine
| Code | CAS No. | Intermediate |
|---|---|---|
| (I)263642-1-a | 98-86-2 | 1-Phenylethan-1-one |
| (II)263642-1-a | 103-67-3 | Benzylmethylamine |
| (III)263642-1-a | 5409-62-1 | 3-[benzyl(methyl)amino]-1-phenylpropan-1-one |
| (IV)263642-1-a | 754155-04-9 | (1R)-3-[Benzyl(methyl)amino]-1-phenylpropan-1-ol |
| (V)263642-1-a | 115290-81-8 | (1R)-3-(Methylamino)-1-phenylpropan-1-ol |
| (VI)263642-1-a | 98-56-6 | 1-Chloro-4-(trifluoromethyl)benzene |
OptimisedRoute 4Steps 5 · Total yield /
(I)263642-2-a2051-95-8(II)263642-2-a25333-24-8(III)263642-2-a—(IV)263642-2-a237769-84-5(V)263642-2-a237769-85-6(VI)263642-2-a237769-86-7(VII)263642-2-a114133-37-8(VIII)263642-2-a98-56-6API · R-fluoxetine
| Code | CAS No. | Intermediate |
|---|---|---|
| (I)263642-2-a | 2051-95-8 | 3-Benzoylpropanoic acid |
| (II)263642-2-a | 25333-24-8 | Methyl 4-oxo-4-phenylbutanoate |
| (III)263642-2-a | - | (5S)-5-phenyloxolan-2-one |
| (IV)263642-2-a | 237769-84-5 | (4S)-4-hydroxy-4-phenylbutanamide |
| (V)263642-2-a | 237769-85-6 | (6S)-6-phenyl-1,3-oxazinan-2-one |
| (VI)263642-2-a | 237769-86-7 | (6S)-3-methyl-6-phenyl-1,3-oxazinan-2-one |
| (VII)263642-2-a | 114133-37-8 | (1S)-3-(Methylamino)-1-phenylpropan-1-ol |
| (VIII)263642-2-a | 98-56-6 | 1-Chloro-4-(trifluoromethyl)benzene |
OptimisedRoute 5Steps 6 · Total yield /
(I)263642-3-a936-59-4(II)263642-3-a18776-12-0(III)263642-3-a293322-40-4(IV)263642-3-a—(V)263642-3-a402-45-9(VI)263642-3-a114446-48-9API · R-fluoxetine
| Code | CAS No. | Intermediate |
|---|---|---|
| (I)263642-3-a | 936-59-4 | 2-Benzoylethyl chloride |
| (II)263642-3-a | 18776-12-0 | 3-Chloro-1-phenylpropan-1-ol |
| (III)263642-3-a | 293322-40-4 | 3-Chloro-1-phenylpropyl butanoate |
| (IV)263642-3-a | - | (+)-3-Chloro-1(R)-phenylpropan-1-ol |
| (V)263642-3-a | 402-45-9 | 4-(Trifluoromethyl)phenol |
| (VI)263642-3-a | 114446-48-9 | (1R)-3-Chloro-1-phenylpropyl 4-(trifluoromethyl)phenyl ether |
OptimisedRoute 6Steps 5 · Total yield /
(I)263642-6-a100-42-5(II)263642-6-a25779-13-9(III)263642-6-a40435-14-1(IV)263642-6-a73627-97-1(V)263642-6-a138750-31-9(VI)263642-6-a98-56-6(VII)263642-6-a130194-43-3(VIII)263642-6-a79-22-1(IX)263642-6-a1245944-25-5API · R-fluoxetine
| Code | CAS No. | Intermediate |
|---|---|---|
| (I)263642-6-a | 100-42-5 | Ethenylbenzene |
| (II)263642-6-a | 25779-13-9 | (1S)-1-phenylethane-1,2-diol |
| (III)263642-6-a | 40435-14-1 | (1S)-2-{[(4-methylbenzene)sulfonyl]oxy}-1-phenylethan-1-ol |
| (IV)263642-6-a | 73627-97-1 | (3R)-3-Hydroxy-3-phenylpropanenitrile |
| (V)263642-6-a | 138750-31-9 | (1R)-3-Amino-1-phenylpropan-1-ol |
| (VI)263642-6-a | 98-56-6 | 1-Chloro-4-(trifluoromethyl)benzene |
| (VII)263642-6-a | 130194-43-3 | 3(R)-Phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine |
| (VIII)263642-6-a | 79-22-1 | Carbonochloridic acid methyl ester |
| (IX)263642-6-a | 1245944-25-5 | Methyl [(3R)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]carbamate |
OptimisedRoute 7Steps 5 · Total yield /
(I)263642-7-a614-16-4(IIa)263642-7-a73627-97-1(IIb)263642-7-a17190-29-3(III)263642-7-a138750-31-9(IVa)263642-7-a541-41-3(IVb)263642-7-a79-22-1(Va)263642-7-a502697-62-3(Vb)263642-7-a2166266-25-5(VI)263642-7-a115290-81-8(VII)263642-7-a98-56-6(VIII)263642-7-a138614-32-1(IX)263642-7-a1245944-25-5(X)263642-7-a100-52-7(XI)263642-7-a52324-04-6API · R-fluoxetine
| Code | CAS No. | Intermediate |
|---|---|---|
| (I)263642-7-a | 614-16-4 | 3-Oxo-3-phenylpropanenitrile |
| (IIa)263642-7-a | 73627-97-1 | (3R)-3-Hydroxy-3-phenylpropanenitrile |
| (IIb)263642-7-a | 17190-29-3 | 3-Hydroxy-3-phenylpropanenitrile |
| (III)263642-7-a | 138750-31-9 | (1R)-3-Amino-1-phenylpropan-1-ol |
| (IVa)263642-7-a | 541-41-3 | Carbonochloridic acid ethyl ester |
| (IVb)263642-7-a | 79-22-1 | Carbonochloridic acid methyl ester |
| (Va)263642-7-a | 502697-62-3 | Ethyl [(3R)-3-hydroxy-3-phenylpropyl]carbamate |
| (Vb)263642-7-a | 2166266-25-5 | Methyl [(3R)-3-hydroxy-3-phenylpropyl]carbamate |
| (VI)263642-7-a | 115290-81-8 | (1R)-3-(Methylamino)-1-phenylpropan-1-ol |
| (VII)263642-7-a | 98-56-6 | 1-Chloro-4-(trifluoromethyl)benzene |
| (VIII)263642-7-a | 138614-32-1 | (3R)-3-Phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine hydrochloride |
| (IX)263642-7-a | 1245944-25-5 | Methyl [(3R)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]carbamate |
| (X)263642-7-a | 100-52-7Available | Benzaldehyde |
| (XI)263642-7-a | 52324-04-6 | Ethynamine |
OptimisedRoute 8Steps 7 · Total yield /
(I)263642-13-a104-55-2(II)263642-13-a91-00-9(III)263642-13-a169698-48-0(IV)263642-13-a73183-34-3(Va)263642-13-a—(Vb)263642-13-a—(VI)263642-13-a—(VIIa)263642-13-a—(VIIb)263642-13-a—(VIIIa)263642-13-a1620141-94-7(VIIIb)263642-13-a—(IXa)263642-13-a42142-52-9(IXb)263642-13-a115290-81-8(Xa)263642-13-a—(Xb)263642-13-a—(XI)263642-13-a98-56-6(XII)263642-13-a—API · R-fluoxetine
| Code | CAS No. | Intermediate |
|---|---|---|
| (I)263642-13-a | 104-55-2 | 3-Phenyl-2(E)-propenal |
| (II)263642-13-a | 91-00-9 | 1,1-Diphenylmethylamine |
| (III)263642-13-a | 169698-48-0 | 1,1-Diphenyl-N-[(1E,2E)-3-phenylprop-2-en-1-ylidene]methanamine |
| (IV)263642-13-a | 73183-34-3Available | 4,4,4',4',5,5,5',5'-Octamethyl-2,2'-bi-1,3,2-dioxaborolane |
| (Va)263642-13-a | - | 1,1-Diphenyl-N-[(1E)-3-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propylidene]methanamine |
| (Vb)263642-13-a | - | 1,1-Diphenyl-N-[(1E,3R)-3-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propylidene]methanamine |
| (VI)263642-13-a | - | Aminomethane |
| (VIIa)263642-13-a | - | N-[(1E)-3-Phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propylidene]methanamine |
| (VIIb)263642-13-a | - | N-[(1E,3R)-3-Phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propylidene]methanamine |
| (VIIIa)263642-13-a | 1620141-94-7 | N-Methyl-3-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-amine |
| (VIIIb)263642-13-a | - | (3R)-N-Methyl-3-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-amine |
| (IXa)263642-13-a | 42142-52-9 | (+/-)-n-Methyl-3-hydroxy-3-phenylpropylamine |
| (IXb)263642-13-a | 115290-81-8 | (1R)-3-(Methylamino)-1-phenylpropan-1-ol |
| (Xa)263642-13-a | - | Sodium 3-(methylamino)-1-phenylpropan-1-olate |
| (Xb)263642-13-a | - | Sodium (1R)-3-(methylamino)-1-phenylpropan-1-olate |
| (XI)263642-13-a | 98-56-6 | 1-Chloro-4-(trifluoromethyl)benzene |
| (XII)263642-13-a | - | (+/-)-N-Methyl-3-phenyl-[3-[4-(trifluoromethyl)phenoxy]propylamine] |
OptimisedRoute 9Steps 4 · Total yield /
(I)131699-11-a2051-95-8(II)131699-11-a111138-03-5(III)131699-11-a406218-17-5(IV)131699-11-a406218-18-6(V)131699-11-a98-56-6(VI)131699-11-a—API · R-fluoxetine
| Code | CAS No. | Intermediate |
|---|---|---|
| (I)131699-11-a | 2051-95-8 | 3-Benzoylpropanoic acid |
| (II)131699-11-a | 111138-03-5 | (5R)-5-Phenyloxolan-2-one |
| (III)131699-11-a | 406218-17-5 | (4R)-4-Hydroxy-4-phenylbutanamide |
| (IV)131699-11-a | 406218-18-6 | (6R)-6-Phenyl-1,3-oxazinan-2-one |
| (V)131699-11-a | 98-56-6 | 1-Chloro-4-(trifluoromethyl)benzene |
| (VI)131699-11-a | - | (3R)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine hydrogen chloride |
Frequently asked questions
What are the approved indications of R-fluoxetine?
Approved indications include: 分离性焦虑, Anxiety, Anxiety disorder.
When does the R-fluoxetine patent expire?
No public expiry year is available for R-fluoxetine yet; this page updates once verified.
How many synthesis routes are recorded for R-fluoxetine?
9 synthesis routes are recorded; the shortest is 4 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy R-fluoxetine intermediates?
3 intermediate CAS of R-fluoxetine are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for R-fluoxetine intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-22